Woodstock Corp Purchases 1,631 Shares of Allergan PLC (AGN)
Woodstock Corp boosted its stake in shares of Allergan PLC (NYSE:AGN) by 5.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,538 shares of the company’s stock after buying an additional 1,631 shares during the period. Allergan PLC comprises approximately 1.5% of Woodstock Corp’s holdings, making the stock its 25th largest position. Woodstock Corp’s holdings in Allergan PLC were worth $7,494,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in the stock. Barnett & Company Inc. acquired a new position in Allergan PLC during the first quarter valued at $111,000. Livingston Group Asset Management CO operating as Southport Capital Management acquired a new position in Allergan PLC during the second quarter valued at $125,000. Trust Co. of Vermont boosted its position in Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock valued at $126,000 after buying an additional 89 shares in the last quarter. Integrated Investment Consultants LLC boosted its position in Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock valued at $137,000 after buying an additional 154 shares in the last quarter. Finally, High Point Bank & Trust Co. boosted its position in Allergan PLC by 19.9% in the second quarter. High Point Bank & Trust Co. now owns 692 shares of the company’s stock valued at $160,000 after buying an additional 115 shares in the last quarter. Hedge funds and other institutional investors own 89.21% of the company’s stock.
Allergan PLC (NYSE:AGN) traded down 0.33% during midday trading on Monday, reaching $191.14. The company’s stock had a trading volume of 7,201,103 shares. The firm has a market cap of $71.69 billion, a price-to-earnings ratio of 5.36 and a beta of 1.08. The company’s 50-day moving average is $217.02 and its 200 day moving average is $233.89. Allergan PLC has a 12-month low of $186.34 and a 12-month high of $322.68.
Allergan PLC (NYSE:AGN) last released its earnings results on Wednesday, November 2nd. The company reported $3.32 EPS for the quarter, missing analysts’ consensus estimates of $3.65 by $0.33. The business had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.73 billion. Allergan PLC had a net margin of 93.74% and a return on equity of 7.26%. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company posted $3.48 EPS. Equities analysts forecast that Allergan PLC will post $13.37 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 28th. Stockholders of record on Tuesday, February 28th will be paid a dividend of $0.70 per share. This is a boost from Allergan PLC’s previous quarterly dividend of $0.05. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.46%.
AGN has been the topic of several research analyst reports. Leerink Swann boosted their price objective on Allergan PLC from $272.00 to $294.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 27th. Goldman Sachs Group Inc. reissued a “buy” rating on shares of Allergan PLC in a research report on Monday, September 12th. William Blair started coverage on Allergan PLC in a research report on Monday. They issued a “market perform” rating on the stock. JPMorgan Chase & Co. set a $325.00 price target on Allergan PLC and gave the company a “buy” rating in a research report on Friday, August 5th. Finally, Zacks Investment Research cut Allergan PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, July 26th. Seven analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. Allergan PLC presently has a consensus rating of “Buy” and a consensus target price of $289.11.
In other Allergan PLC news, CEO Brent L. Saunders bought 5,250 shares of the business’s stock in a transaction dated Monday, November 21st. The shares were purchased at an average price of $189.13 per share, with a total value of $992,932.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Maria Teresa Hilado bought 1,422 shares of the business’s stock in a transaction dated Friday, November 11th. The shares were acquired at an average cost of $210.64 per share, for a total transaction of $299,530.08. Following the purchase, the chief financial officer now owns 12,659 shares of the company’s stock, valued at approximately $2,666,491.76. The disclosure for this purchase can be found here. Insiders own 0.27% of the company’s stock.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related stocks with our FREE daily email newsletter.